The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the USFDA.
This article will define the types of biologics being tested to treat lupus, the specific drugs used for lupus treatment, and the benefits and risks of these types of treatments. What Are Biologics? Biologics are a type of treatment new to the market over the last few decades.
The development of 2 lupus therapiesan experimental immunosuppressant designed to treat lupus new treatments for these challenging
In 20, two new drugs (anifrolumab and voclosporin) were approved for the treatment of lupus or lupus nephritis; and a third one, belimumab (previously approved for the treatment of lupus), was approved for the treatment of lupus nephritis.
In recent yers, new drugs (anifrolumab and voclosporin) were approved for the treatment of lupus or lupus nephritis; and a third one
A new biologic, anifrolumab (Saphnelo), has been approved for systemic lupus erythematosus (SLE), the first new lupus drug since 2024.
This news follows the FDA-approval of belimumab (Benlysta) for lupus nephritis in December 2024, when it became first drug ever to be approved specifically for lupus nephritis. Belimumab, which is manufactured by GlaxoSmithKline, was approved in 2024 for the treatment of lupus but not specifically for lupus nephritis.
The pipeline of potential new treatments for lupus remains vibrant, and the Lupus Foundation of America continues its work to bring down barriers to lupus drug development and ensure that people with lupus will have access to the medications they need to improve their quality of life.
Another new drug in lupus treatment is an oral medicine called voclosporin, which is a type of calcineurin inhibitor. Calcineurin
Comments